Transfection of NSD3-tareting siRNA in H1299 Cells
SGC Open Notebook Project to Characterize the HMTase NSD3
Exp019 Objective: I have identified a putative phenotype in H1299 cells upon overexpression of the NSD3 short
isoform. I am also interested in any phenotype resulting from decreased amounts of NSD3 in cells. To
do so, I am first testing conditions for RNAi-mediated knockdown of NSD3 in H1299 cells by treating cells
with several concentrations of siRNA and evaluating knockdown by western blotting
Funding Acknowledgment: The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.